Craving respiratory dominance, AstraZeneca inks $2.1B deal for Almirall’s lung meds

Tracy Staton

has agreed to pay $ 875 million up front–and up to $ 2.2 billion total, with milestones–for Almirall's portfolio. The brings a couple of marketed drugs, and a list of pipeline that includes a combo drug Almirall is developing with U.S.-based Forest Laboratories.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS